GUOBANG PHARMA LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.49 CNY | -0.64% |
|
+3.88% | +5.30% |
| Apr. 15 | Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Jan. 27 | Guobang Pharma Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 5.91B 816M | Sales 2025 * | 7.52B 1.04B | Capitalization | 10.27B 1.42B |
|---|---|---|---|---|---|
| Net income 2024 * | 722M 99.76M | Net income 2025 * | 1.12B 155M | EV / Sales 2024 * | 1.74 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.37 x |
| P/E ratio 2024 * |
14.3
x | P/E ratio 2025 * |
9.2
x | Employees | 4,231 |
| Yield 2024 * |
3.41% | Yield 2025 * |
4% | Free-Float | 28.69% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.64% | ||
| 1 week | +3.88% | ||
| Current month | +10.98% | ||
| 1 month | +15.42% | ||
| 3 months | +18.68% | ||
| 6 months | -4.79% | ||
| Current year | +5.30% |
1 week
17.88
18.89
1 month
15.7118.89
Current year
13.0118.89
1 year
13.0122.67
3 years
13.0147.90
5 years
13.0147.90
10 years
13.0147.90
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Da Gong
DFI | Director of Finance/CFO | 56 | - |
Shi Xue Liao
PSD | President | 49 | - |
Jia Jun Qiu
CHM | Chairman | 59 | 95-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Ming Wu
BRD | Director/Board Member | 69 | 19-10-17 |
Jia Jun Qiu
CHM | Chairman | 59 | 95-12-31 |
Shi Xue Liao
PSD | President | 49 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.77% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 18.49 | -0.64% | 3 206 400 |
| 24-05-20 | 18.61 | -0.43% | 4,876,307 |
| 24-05-17 | 18.69 | +1.85% | 8,193,150 |
| 24-05-16 | 18.35 | +1.83% | 5,602,200 |
| 24-05-15 | 18.02 | -1.42% | 5,968,000 |
End-of-day quote Shanghai S.E., May 20, 2024
More quotes
Guobang Pharma Ltd is a China-based company mainly engaged in the research and development, production, and sales of related products in the field of medicine and animal health products. The Company's pharmaceutical business includes raw materials, key pharmaceutical intermediates and preparations, and its main products include azithromycin, clarithromycin, and roxithromycin cephalosporin series products. The animal health products business includes animal protection raw materials, animal protection additives and preparations. The main products of veterinary antibiotics include florfenicol, enrofloxacin series, etc., and insecticides include diclazuril and cypronamine, and reparation products include premixes, powders, granules, etc.
Sector
Pharmaceuticals
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
18.49
CNY
Average target price
23
CNY
Spread / Average Target
+24.39%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +5.30% | 1.43B | |
| +37.78% | 705B | |
| +32.82% | 583B | |
| -3.51% | 364B | |
| +19.94% | 332B | |
| +5.14% | 291B | |
| +16.64% | 238B | |
| -4.13% | 210B | |
| +10.63% | 209B | |
| +9.32% | 169B |
- Stock Market
- Equities
- 605507 Stock
